Assessment of Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia
Status:
Suspended
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind placebo controlled study to determine the safety and efficacy of
Angiogenic Cell Precursors (ACPs) in relieving symptoms of Critical Limb Ischemia in patients
treated with standard of care and with no surgical revascularization option. It is assumed
that the ACP-treated group will have a lower amputation and death rate as compared to the
placebo group. Other hemodynamic, imaging and clinical parameters will also be compared
between the two groups. Quality of life assessments will also be performed.